RGLS — Regulus Therapeutics Share News
0.000.00%
Last trade - 00:00- $563.57m
- $498.20m
U.S. STOCKS ON THE MOVE-Perrigo, FG Financial, Alector
U.S. STOCKS ON THE MOVE-Metal miners, Rambus, Nuwellis
Regulus jumps on promising early data of kidney disease treatment
Brief: Regulus Therapeutics Announces Positive Topline Safety And Pharmacokinetic Data From The Phase 1 Single-Ascending Dose Clinical Trial
Brief: Regulus Therapeutics Reports Second Quarter 2022 Financial Results
Regulus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Netflix, Kraft Heinz, travel stocks
U.S. STOCKS ON THE MOVE-Cruise stocks, Advent Technologies, Expensify Inc
Regulus drops after partner Sanofi ends genetic disorder drug study
Brief: Regulus Therapeutics Reports Sanofi Notified Co Of Its Decision To Terminate Study Of Lademirsen
Brief: Regulus Therapeutics Announces Receipt Of FDA Orphan Drug Designation For Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Brief: Regulus Therapeutics Announces First Subject Dosed In Phase 1 Single-Ascending Dose Clinical Trial Of RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease
Regulus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Regulus Therapeutics gain on FDA nod for kidney disorder therapy study
Brief: Regulus Therapeutics Announces FDA Acceptance Of IND Application For RGLS8429 For Treatment Of ADPKD
Regulus Therapeutics Inc expected to post a loss of 5 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Allego, WeWork, Emclaire
Regulus Therapeutics up on starting preclinical ALS studies